Search

Point-of-Care-Testing (PoCT) has emerged as an essential component of modern healthcare, providing rapid, low-cost, and simple diagnostic options. The integration of Machine Learning (ML) into biosensors has ushered in a new era of innovation in the field of PoCT. This article investigates the numerous uses and transformational possibilities of ML in improving biosensors for PoCT. ML algorithms, which are capable of processing and interpreting complicated biological data, have transformed the accuracy, sensitivity, and speed of diagnostic procedures in a variety of healthcare contexts. This review explores the multifaceted applications of ML models, including classification and regression, displaying how they contribute to improving the diagnostic capabilities of biosensors. The roles of ML-assisted electrochemical sensors, lab-on-a-chip sensors, electrochemiluminescence/chemiluminescence sensors, colorimetric sensors, and wearable sensors in diagnosis are explained in detail. Given the increasingly important role of ML in biosensors for PoCT, this study serves as a valuable reference for researchers, clinicians, and policymakers interested in understanding the emerging landscape of ML in point-of-care diagnostics.

A novel, portable deep learning-assisted smartphone-based electrochemiluminescence (ECL) cost-effective (~10$) sensing platform was developed and used for selective detection of lactate. Low-cost, fast prototyping screen printing and wax printing methods with paper-based substrate were used to fabricate miniaturized single-pair electrode ECL platforms. The lab-made 3D-printed portable black box served as a reaction chamber. This portable platform was integrated with a smartphone and a buck-boost converter, eliminating the need for expensive CCD cameras, photomultiplier tubes, and bulky power supplies. This advancement makes this platform ideal for point-of-care testing applications. Foremost, the integration of a deep learning approach served to enhance not just the accuracy of the ECL sensors, but also to expedite the diagnostic procedure. The deep learning models were trained (3600 ECL images) and tested (900 ECL images) using ECL images obtained from experimentation. Herein, for user convenience, an Android application with a graphical user interface was developed. This app performs several tasks, which include capturing real-time images, cropping them, and predicting the concentration of required bioanalytes through deep learning. The device's capability to work in a real environment was tested by performing lactate sensing. The fabricated ECL device shows a good liner range (from 50 µM to 2000 µM) with an acceptable limit of detection value of 5.14 µM. Finally, various rigorous analyses, including stability, reproducibility, and unknown sample analysis, were conducted to check device durability and stability. Therefore, the developed platform becomes versatile and applicable across various domains by harnessing deep learning as a cutting-edge technology and integrating it with a smartphone.

Coenzyme-Q10 (CoQ10) is a hydrophobic benzoquinone with antioxidant and anti-inflammatory properties. It is known to reduce oxidative stress in various health conditions. However, due to the low solubility, permeability, stability, and poor oral bioavailability, the oral dose of CoQ10 required for the desired therapeutic effect is very high. In the present study, CoQ10 is encapsulated into two milk derived proteins β-lactoglobulin and lactoferrin (BLG and LF) to produce self-assembled nanostructures of around 100-300 nm with high encapsulation efficiency (5-10% w/w). Both CoQ10-BLG and CoQ10-LF nanoparticles (NPs) significantly improved the aqueous solubility of CoQ10 60-fold and 300-fold, compared to CoQ10 alone, which hardly dissolves in water. Insight into the difference in solubility enhancement between BLG and LF was obtained using in silico modeling, which predicted that LF possesses multiple prospective CoQ10 binding sites, potentially enabling greater loading of CoQ10 on LF compared to BLG, which was predicted to be less capable of binding CoQ10. At pH 7.4, CoQ10-LF NPs showed a burst release between 30 min and 2 h then plateaued at 12 h with 30% of the total drug released over 48 h. However, pure CoQ10-BLG and pure CoQ10 had a significantly lower release rate with less than 15% and 8% cumulative release in 48 h, respectively. Most importantly, both BLG and LF NPs significantly improved CoQ10 permeability compared to the pre-dissolved drug across the Caco-2 monolayer with up to 2.5-fold apparent permeability enhancement for CoQ10-LF─further confirming the utility of this nanoencapsulation approach. Finally, in murine macrophage cells (J774A.1), CoQ10-LF NPs displayed significantly higher anti-ROS properties compared to CoQ10 (predissolved in DMSO) without affecting the cell viability. This study paves the way in improving oral bioavailability of poorly soluble drugs and nutraceuticals using milk-based self-assembled nanoparticles.

Coenzyme Q10 is a potent antioxidant that plays an important role in the maintenance of various biochemical pathways of the body and has a wide range of therapeutic applications. However, it has low aqueous solubility and oral bioavailability. Mesoporous silica nanoparticles (MCM-41 and SBA-15 types) exhibiting varying pore sizes and modified with phosphonate and amino groups were used to study the influence of pore structure and surface chemistry on the solubility, in vitro release profile, and intracellular ROS inhibition activity of coenzyme Q10. The particles were thoroughly characterized to confirm the morphology, size, pore profile, functionalization, and drug loading. Surface modification with phosphonate functional groups was found to have the strongest impact on the solubility enhancement of coenzyme Q10 when compared to that of pristine and amino-modified particles. Phosphonate-modified MCM-41 nanoparticles (i.e., MCM-41-PO 3 ) induced significantly higher coenzyme Q10 solubility than the other particles studied. Furthermore, MCM-41-PO 3 led to a twofold decrease in ROS generation in human chondrocyte cells (C28/I2), compared to the free drug in a DMSO/DMEM mixture. The results confirmed the significant contribution of small pore size and negative surface charge of MSNs that enable coenzyme Q10 confinement to allow enhanced drug solubility and antioxidant activity.

Miniaturized microfluidic electrochemical energy devices can produce power without the need for a separator reducing a considerable amount of fabrication complications. Enzymatic biofuel cells, with glucose as a fuel, are capable of producing energy from biological fluids in the presence of biocatalysts. The tedious fabrication procedures can be avoided by making electrodes and microchannel using laser ablation technique on polyimide substrates. In this work, a microfluidic enzymatic biofuel cell (MEBFC) has been presented with CO 2 laser-ablated microchannel and bioelectrodes using a mediatorless approach. Multiwalled carbon nanotubes (MWCNT) have been used as a promoter to enhance the electron transfer rate. The fabricated MEBFC shows good power performance supplying [Formula: see text]/cm 2 with a maximum open-circuit voltage of 260 mV.

In the above article [1], the caption of Fig. 2 should read "Fig. 2. Images of untreated (bare) and surface modified BPs. (a) and (b) SEM images of bare BP (different magnification). (c) and (d) SEM images of GOx immobilized BP (different magnification). (e) and (f) SEM images of Laccase immobilized BP (different magnification). Copyright Permission from IEEE [2]."

Microfluidic microbial fuel cells (μ-MFCs) have received considerable attention due to their ability to generate green and qualitative self-sustainable energy. Several electrodes and device fabrication methodologies, and various electrochemically active bacteria (EABs), along with their effect on MFC performance with various operating parameters, have been well reported. However, shorter life, lower throughput, and high operating and maintenance overheads are major impediments to their development towards commercialization. In this context, simple and cost-effective bioelectrodes using printed circuit board (PCB) and a polymer based microchannel have been fabricated using modern photolithography and soft-lithography techniques respectively. Furthermore, the etched PCB electrodes were patterned with multi-walled carbon nanotubes (MWCNT). Subsequently, these bioelectrodes were assembled over a Y-shaped microchannel and tested under a co-laminar microfluidic flow environment powered by Shewanella putrefaciens. Various volumetric bacterial experiments and flow rate studies have also been conducted to find the most appropriate optimum bacterial volume and power efficiency. Subsequently, extensive potentiometric electrochemical studies, such as Open Circuit Potential (OCP) and polarization analysis, were accomplished using electrochemical workstation. This well-developed handheld μ-MFCs yields a maximum open circuit potential 395 mV with maximum power density of 239.2 μW/cm 2 (3.271 mA/cm 2 ) at optimized parameters., (Copyright © 2021 Elsevier Ltd. All rights reserved.)

Oral vaccine has attracted much interest, as it can stimulate both mucosal and systemic immunity with noninvasive and good patient compliance. However, the oral vaccine efficiency is strongly constrained by the low absorption of antigens in the small intestine due to the mucosal barriers. Physicochemical characteristics of nanoparticles (NPs) have strong effects on antigen mucosal penetration, helping to improve immune response. However, surface functions of NPs on mucosal transportation have not been clearly understood. In this work, we elaborately investigated how the surface characteristics of mucoadhesive chitosan and its derivant act on oral antigen absorption and immune response. Core-shell chitosan- and o -carboxymethyl chitosan-coated calcium phosphate (CaP) nanocomposites have been fabricated to investigate the surface property effect on protein antigen delivery using the oral route. The interaction between polymer-coated CaP NPs and the intestinal mucosal layer was studied using mucin absorption, NP diffusion through the mucus layer, NP permeability across the epithelium monolayer, and their cellular uptake by antigen presenting cells in detail. Ex vivo mucosa distribution and in vivo oral immunization of polymer-coated CaP nanocomposites were further examined to demonstrate that the surface property of NPs affects CaP diffusion and penetration through the mucosal layer. As expected, OVA orally delivered by polymer-coated CaP nanocomposites improved the response of mucosal immunity compared to antigen OVA itself in vivo .

Macromolecular therapeutics of biological origin, also known as biologics, have become one of the fastest-growing classes of drugs for management of a range of chronic and acute conditions. The majority of approved biologics are administered via the parenteral route and are thus expensive, have low patient compliance, and have high systemic toxicity. Therefore, tremendous efforts have been devoted to the development of carriers for oral delivery of biologics. This review evaluates key chemical (e.g. pH and enzymes) and physiological challenges to oral biologics delivery. We review the conventional formulation strategies and their limitations, followed by a detailed account of the progress on the use of nanocarriers used for oral biologics delivery, covering organic and inorganic nanocarriers. Lastly, we discuss limitations and opportunities presented by these emerging nanomaterials in oral biologics delivery., Competing Interests: Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier Ltd. All rights reserved.)

Atopic dermatitis (AD) is a repetitive inflammatory skin disorder with limited treatment options. Innovative targeted therapies are gaining significant interest and momentum towards disease control including better ways to deliver drugs topically. Tacrolimus is one such compound which is used to manage moderate to severe AD without causing atrophy which is one of the common side effects of steroids. However, Tacrolimus suffers from poor solubility and retention in the skin when used alone in hydrogel. Therefore, we have prepared Tacrolimus loaded mesoporous silica nanoparticles (TMSNs) to overcome the issues related to its solubility and effective topical delivery. Mesoporous silica nanoparticles (MSNs) were synthesized using sol gel technique and surface functionalized using amino (-NH 2 + ) and phosphonate (-PO 3 - ) groups. Tacrolimus was loaded into MSNs and the particles were characterized for particle size (TEM and DLS), zeta potential (DLS), solubility studies, FTIR, TGA, XRD, BET and cytotoxicity studies. Water solubility of Tacrolimus was increased by 7 folds with phosphonate functionalized MSNs compared to free Tacrolimus. Further the TMSNs were incorporated in to carbopol gel, and the gel formulation was evaluated for various gel characterization tests (pH, spreadability, viscosity), in vitro tests (drug release, permeability studies) and in vivo tests (skin irritation study and efficacy studies) using 1-Fluoro-2,4-dinitrobenzene (DNFB) induced dermatitis in Balb/c mice. Results of in vitro and in vivo study showed that TMSNs loaded gel showed significantly higher amount of Tacrolimus retained (ex vivo - rat skin) and much higher reduction in ear thickness and improved histology (in vivo - in mice). Our data collectively suggest that MSNs incorporated hydrogel as a promising new formulation strategy for topical delivery of poorly soluble drugs., (Copyright © 2021 Elsevier B.V. All rights reserved.)

Extracellular vesicles (EVs) can transfer intercellular messages in various (patho)physiological processes and transport biomolecules to recipient cells. EVs possess the capacity to evade the immune system and remain stable over long periods, identifying them as natural carriers for drugs and biologics. However, the challenges associated with EVs isolation, heterogeneity, coexistence with homologous biomolecules, and lack of site-specific delivery, have impeded their potential. In recent years, the amalgamation of EVs with rationally engineered nanostructures has been proposed for achieving effective drug loading and site-specific delivery. With the advancement of nanotechnology and nanoarchitectonics, different nanostructures with tunable size, shapes, and surface properties can be integrated with EVs for drug loading, target binding, efficient delivery, and therapeutics. Such integration may enable improved cellular targeting and the protection of encapsulated drugs for enhanced and specific delivery to target cells. This review summarizes the recent development of nanostructure amalgamated EVs for drug delivery, therapeutics, and real-time monitoring of disease progression. With a specific focus on the exosomal cargo, diverse drug delivery system, and biomimetic nanostructures based on EVs for selective drug delivery, this review also chronicles the needs and challenges of EV-based biomimetic nanostructures and provides a future outlook on the strategies posed., (© 2021 Wiley-VCH GmbH.)

Site specific oral delivery of many biopharmaceutical classification system (BCS) class II and IV drugs is challenging due to their poor solubility, low permeability and degradation in the gastrointestinal tract. Whilst colloidal carriers have been used to improve the bioavailability of such drugs, most nanocarriers based drug delivery systems suffer from multiple disadvantages, including low encapsulation efficiency (liposomes, polymeric nanoparticles), complex synthesis methods (silica, silicon-based materials) and poorly understood biodegradability (inorganic nanoparticles). Herein, a novel pH responsive nanocolloids were self-assembled using natural compounds such as bovine β-lactoglobulin (BLG) and succinylated β-lactoglobulin (succ. BLG) cross-linked with epsilon poly l-lysine (BCEP and BCP), and found to possess high loading capacity, high aqueous solubility and site-specific oral delivery of a poorly soluble nutraceutical (curcumin), improving its physicochemical properties and biological activity in-vitro and ex-vivo. Our optimized synthesis formed colloids of around 200 nm which were capable of encapsulating curcumin with ~100% encapsulation efficiency and ~10% w/w drug loading. By forming nanocomplexes of curcumin with BLG and succ. BLG, the aqueous solubility of curcumin was markedly increased by ~160-fold and ~86-fold, respectively. Encapsulation with BLG increased the solubility, whereas succ. BLG prevent release of encapsulated curcumin when subjected to gastric fluids as it is resistant to breakdown on exposure to pepsin at acidic pH. In conditions mimicking the small intestine, Succ. BLG was more soluble resulting in sustained release of the encapsulated drug at pH 7.4. Additionally, crosslinking succ. BLG with E-PLL significantly enhanced curcumin's permeability in an in-vitro Caco-2 cell monolayer model compared to curcumin solution (dissolved in 1% DMSO), or non-crosslinked BLG/succ. and BLG. In a mouse-derived intestinal epithelial 3D organoid culture stimulated with IL-1β, BLG-CUR and crosslinked BCEP nanoparticles reduced the production of inflammatory cytokines and chemokines such as Tnfα and Cxcl10 more than curcumin solution or suspension while these nanoparticles were non-toxic to organoids. Overall this work demonstrates the promise of nutraceutical-based hybrid self-assembled colloidal system to protect hydrophobic drugs from harsh gastrointestinal conditions and improve their solubility, dissolution, permeability and biological activity., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 Elsevier Inc. All rights reserved.)

Glioblastoma (GBM) is one of the most aggressive cancers of the brain. Despite extensive research over the last several decades, the survival rates for GBM have not improved and prognosis remains poor. To date, only a few therapies are approved for the treatment of GBM with the main reasons being: 1) significant tumour heterogeneity which promotes the selection of resistant subpopulations 2) GBM induced immunosuppression and 3) fortified location of the tumour in the brain which hinders the delivery of therapeutics. Existing therapies for GBM such as radiotherapy, surgery and chemotherapy have been unable to reach the clinical efficacy necessary to prolong patient survival more than a few months. This comprehensive review evaluates the current and emerging therapies including those in clinical trials that may potentially improve both targeted delivery of therapeutics directly to the tumour site and the development of agents that may specifically target GBM. Particular focus has also been given to emerging delivery technologies such as focused ultrasound, cellular delivery systems nanomedicines and immunotherapy. Finally, we discuss the importance of developing novel materials for improved delivery efficacy of nanoparticles and therapeutics to reduce the suffering of GBM patients., (Copyright © 2021 Elsevier B.V. All rights reserved.)

Resveratrol (RES) is a nutraceutical with promising anti-inflammatory properties for the treatment of inflammatory bowel diseases (IBD). However, the clinical effectiveness of resveratrol as an oral anti-inflammatory agent is hindered by its extremely poor solubility and poor stability. In this study, we encapsulated resveratrol in β-lactoglobulin (BLG) nanospheres and systematically analyzed their formulation parameters in vitro followed by a thorough in vivo anti-inflammatory testing in a highly specialized spontaneous murine UC model (Winnie mice model). Complexation of resveratrol with BLG increased the aqueous solubility of resveratrol by ≈1.7 times with 10% w/w loading. Additionally, the in vitro dissolution of resveratrol from the particles was found to be higher compared to resveratrol alone, resulting in >90% resveratrol dissolution in ∼8 h. The anti-inflammatory activity of resveratrol was examined for the first time in Winnie mice, a mouse model that closely represents the clinical signs of IBD. At a 50 mg/kg oral dose for 2 weeks, BLG-RES significantly improved both % body weight and disease activity index (DAI), compared to free resveratrol in Winnie mice. Importantly, histological evaluations revealed a similar trend with striking improvement in the pathology of the colon via an increase in goblet cell numbers and recovery of colonic epithelium. BLG-RES significantly increased the expression level of cytokine interleukin-10 ( Il10 ), which confirms the reduction in inflammation potentially because of the increased dissolution and stability of resveratrol by complexation with BLG. This comprehensive study demonstrates the effectiveness of biocompatible nanomaterials such as BLG in oral delivery of poorly soluble anti-inflammatory molecules such as resveratrol in the treatment of IBD.

The present work demonstrates a miniaturized 3D printed Electrochemiluminescence (ECL) sensing platform with Laser-Induced Graphene (LIG) based Open Bipolar Electrodes (OBEs). To fabricate OBEs, polyimide (PI) substrate has been used as it provides properties like low-cost fabrication, high selectivity, great stability, easy reproducibility, cost-effectiveness and rapid prototyping. Moreover, graphene can be created on PI in a single step during the ablation of the CO 2 laser. Android smartphone was efficiently used to sense ECL signals as well as to drive the required voltage to the OBEs. With the optimized parameters, the imaging system was successfully used to detect Hydrogen Peroxide (H 2 O 2 ) with a linear range of 1 [Formula: see text] to [Formula: see text] and detection of limit (LOD) [Formula: see text] (R 2 = 0.9449, n = 3). In addition, the detection of glucose has been carried out with a linear range of [Formula: see text] to [Formula: see text] and detection of limit (LOD) [Formula: see text] (R 2 = 0.9875, n = 3). Further, real samples were tested to manifest the workability of the platform for random samples. Overall, the developed low-cost, rapidly realized and the miniaturized system can be used in many biomedical applications, environmental monitoring and point-of-care testings.

Oral ingestion remains as the most convenient route of administration for the application of pharmaceuticals since it is non-invasive and does not require trained personnel to administer the drugs. Despite significant progress in novel oral drug delivery platforms over the past few decades, the oral delivery of macromolecules (particularly for peptides and proteins) is one of the major challenges faced by the biopharmaceutical industry. This is even more important since a large number of biologic drugs have been available in the past decade which typically require intravenous administration. Recently, silica nanoparticles have emerged as multifunctional, biocompatible and biodegradable inorganic nanocarriers with enormous potential as an oral drug delivery platform for various therapeutics including macromolecules. Their unique structural composition facilitates the loading of large therapeutic payloads at desired loading capacities for a controlled and site-specific oral delivery. Here, we review first the physiological challenges for oral delivery of peptides and proteins. Next, we discuss silica-based functional materials for oral delivery of macromolecules and highlight their evolving role not only as an encapsulant but as a permeation enhancer as well. Lastly, we also discuss potential strategies for future translation of these novel materials to the clinic., (Copyright © 2020 Elsevier B.V. All rights reserved.)

Graphite pencil stroked electrodes for paper-based Microfluidic devices are gaining immense attention due to their electrochemical properties, cost efficiency, and ease-of-use. However, their widespread use has been hindered by the challenges associated with their manual fabrication such as non-uniformity in graphite deposition, applied pressure, etc. This work presents the design and development of an automated graphite pencil stroking device for graphite electrode fabrication with high efficiency through a compact, inexpensive and automatic process, with reduced fabrication time and human intervention leading to more uniformity. The motion platform of Graphtec plotter was used to create multiple strokes with the help of the proposed device. Such inexpensive graphite electrodes (less than the US $1) have been observed to be porous in nature, acting as diffusion agents. The automated graphite electrodes were used to study the performance of microfluidic paper fuel cells (MPFCs) with formic acid, oxygen, and sulphuric acid acting as fuel, oxidising agent and electrolyte respectively. From this configuration, the maximum current density and power density were measured to be 1,305.5 µA cm -2 and 135.5 µW cm -2 , respectively at 0.3 V stable OCP at 100 strokes. Overall, the study enumerates the development of an automated pencil stroke device for fabricating graphite electrodes, which can potentially be harnessed in numerous miniaturized paper based applications.

Research to develop sustainable, automated and robust Enzymatic Biofuel Cell (EBFC) with high-energy output is hugely driven from its multiple application domains. To this end, continuous work to realize inexpensive and mass-manufacturable bioelectrodes has remained one of the prime challenges. In the present work, such bioelectrodes (both bioanode and biocathode) have been created by leveraging customized and novel 3D printed (3DP) composite Graphene/PLA filaments. The unsophisticated method is cost-effective and rapid, eradicates the requirement of any further amendment and post-processing treatment, and is amenable to print the end product within a short duration. To enhance the surface area and optimize the electrochemical sensing, the fabricated 3DP Graphene/PLA electrodes were treated with dimethylformamide (DMF) solution followed by the immobilization of GOx and laccase enzymes to realize bioanode and biocathode respectively. The morphological and elemental composition study of 3DP, 3DP/DMF treated and enzyme modified electrodes was carried out via scanning electron microscope (SEM) and energy dispersive spectroscopy (EDS) respectively. The electrochemical and polarization performances of the prepared bioelectrodes were evaluated using the linear sweep voltammetry (LSV), cyclic voltammetry (CV), and open circuit potential (OCP). Maximum current density of 1.41 mA/cm 2 at 0.5 V for bioanode at 40 mM glucose concentration, and 0.216 mA/cm 2 at 0.42 V was noticed for biocathode. To provide proof-of-concept, the fabricated bioelectrodes were assembled in a fluidic cell and the polarization performance was studied. Overall, the fabricated 3DP bioelectrode exhibited good stability with reasonably good retention of biocatalytic activity. The fabricated 3DP Composite Graphene/PLA electrodes are promising bioelectrodes material for EBFC and many electrochemical based biochemical sensing applications at the microfluidic level.

This paper demonstrates a simple-in-struct- ure, cost-effective, and environment-friendly Microfluidic Paper-based Analytical Device for Microbial Biofuel Cell ( μ PAD-MBFC). It consists of a microchannel with biofuel cell (Escherichia.Coli) and an oxidant (aerated tap water) flowing co-parallelly over Multiwalled Carbon Nanotube (MWCNT)-based Bucky Paper (BP) electrodes using a self-capillary and co-laminar flow mechanism. The electrochemical studies, such as open circuit potential (OCP) and polarization were evaluated using a potentiostat. Various volumetric bacterial studies were also carried out to find out the best suitable optimal bacterial volume. Subsequently, the morphological and detailed element composition study of electrode surface was performed using scanning electron microscopy (SEM) and energy dispersive spectroscopy (EDS) techniques. This well-designed portable μ PAD-MBFC yields a maximum power density of 4 [Formula: see text]/cm 2 ( [Formula: see text]/cm 2 ) at 0.405 V over [Formula: see text] of culture and leveraging to its long-lasting potential to operate miniaturized microelectronics sensors and portable devices.

This paper establishes a membraneless, co-laminar flow-based approach to develop a cost-effective microfluidic paper-based analytical device for enzymatic biofuel cell ( PAD-EBFC). The developed PAD-EBFC supporting the self-capillary fluid transport action consists of Y-shaped paper microchannel with the fuel (glucose) and oxidant (O 2 ) streaming in parallel over carbon nanotube-based bucky paper electrodes modified with biocompatible electrocatalytic enzymes, such as glucose oxidase and laccase without any additional redox cofactor. The electrochemical performance for the modified bioelectrodes, i.e., electrocatalytic oxidation and reduction reaction, was carried out using linear sweep voltammetry, cyclic voltammetry, and open circuit potential. The overall performance of PAD-EBFC was evaluated using the polarization studies. Subsequently, the catalytic activity of enzymes on the electrode surface was validated by the scanning electron microscope. This simple and portable PAD-EBFC can generate the maximum power density to the order of /cm 2 ( /cm 2 ) at 0.505 V over prolonged durations of around 50 h. Hence, the presented PAD-EBFC shows good power density and stability, leading to its strong potential to power miniaturized microelectronics devices and sensors.